Invention Grant
US09359432B2 Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
有权
使用选择性抑制NGF与TrkA结合的抗NGF抗体预防或治疗疼痛的方法,而不影响NGF与p75的结合
- Patent Title: Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
- Patent Title (中): 使用选择性抑制NGF与TrkA结合的抗NGF抗体预防或治疗疼痛的方法,而不影响NGF与p75的结合
-
Application No.: US14533645Application Date: 2014-11-05
-
Publication No.: US09359432B2Publication Date: 2016-06-07
- Inventor: John A. Latham , Ethan W. Ojala , Jeffrey T. L. Smith , Benjamin H. Dutzar , Leon F. Garcia-Martinez
- Applicant: ALDERBIO HOLDINGS LLC
- Applicant Address: US NV Las Vegas
- Assignee: ALDERBIO HOLDINGS LLC
- Current Assignee: ALDERBIO HOLDINGS LLC
- Current Assignee Address: US NV Las Vegas
- Agency: LeClairRyan, a professional corporation
- Agent Robin L. Teskin
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/22 ; C07K16/28 ; A61K45/06 ; A61K39/00

Abstract:
NGF antagonists including antibodies and antibody fragments thereof having binding specificity to human Nerve Growth Factor (“NGF”), and methods of treating pain. Methods of treating pain or eliciting an analgesic effect in an individual comprising administering an effective amount of an NGF antagonist inhibits the association of NGF with TrkA without inhibiting the association of NGF with p75. The methods may further comprise administering an effective amount of a second anti-human NGF antibody or fragment thereof which inhibits the association of NGF with p75, that may further also inhibit the association of NGF with TrkA.
Public/Granted literature
Information query